Less treatment regret with SBRT, and when patients are fully informed

There is growing recognition that the patient’s satisfaction or regret with his treatment decision is more than just a matter of whether he is happy with the oncological outcome. Satisfaction/regret is the product of many variables, including how well he understood his options, his interactions with his doctors, the side effects he suffered and when he suffered them, his expectations about the side effects of treatment, and cultural factors. … READ MORE …

SBRT vs. moderate hypofractionation: same or better quality of life?

In several randomized clinical trials of external beam treatment of primary prostate cancer, we have seen that moderately hypofractionated intensity-modulated radiation therapy (HypoIMRT), accomplished in 12 to 26 treatments or fractions, is no worse than conventionally fractionated IMRT treatment (in 40 to 44 fractions). … READ MORE …

Hypofractionated radiation therapy using IMRT has a clear advantage

I was reticent to write about hypofractionation yet again after writing about it so often in the last year (see this link for my latest summary). … READ MORE …

An update on the PARTIQoL trial

We have just learned that the randomized clinical trial of proton beam radiation therapy (PBRT) vs. IMRT for men with localized prostate cancer (the so-called PARTIQoL trial) now has 10 active centers recruiting patients and another two centers that expect to start enrolling patients soon. A total of 173 patients have been enrolled to date. … READ MORE …

First data from a RTC of proton beam radiation vs. conventional radiation therapy

When you go to large meetings with thousands of presentations, you miss things. And here’s one that a lot of people seem to have missed — your sitemaster included. … READ MORE …

Hypofractionated radiation therapy with IMRT: same results in less time

The largest-yet randomized clinical trial comparing hypofractionated (fewer treatments or fractions) to normally fractionated intensity-modulated radiation therapy (IMRT) has proved that oncological outcomes and late-term toxicities were the same for both treatment schedules. … READ MORE …

Quality of life after three different first-line radiation therapies for localized disease: Part 3

This is the third and last of three reports discussing a recent, detailed paper by Evans et al. The first (Part 1) was published on Tuesday, August 25, and Part 2 on Wednesday, August 26. … READ MORE …

Quality of life after three different first-line radiation therapies for localized disease: Part 2

This is the second of three reports discussing a recent, detailed paper by Evans et al. The first (Part 1) was published yesterday, on Tuesday, August 25, and Part 3 will be published tomorrow (Thursday, August 27). … READ MORE …

Quality of life after three different first-line radiation therapies for localized disease: Part 1

Some of the leading lights in radiation oncology have collaborated on a study (by Evans et al.) of patient-reported quality of life (QOL) following various primary radiation treatments for prostate cancer. … READ MORE …

PBRT vs. IMRT — patients can now enroll at more sites

The “New” Prostate Cancer InfoLink has consistently encouraged newly diagnosed patients who are thinking about radiation therapy as treatment for low- and intermediate-risk, localized prostate cancer to consider enrolling in the ongoing, randomized, Phase III clinical trial known as the PARTIQoL trial. … READ MORE …

The theoretical tissue-sparing effects of PBRT on non-cancerous tissues

Proponents of proton beam radiation therapy (PBRT) have long touted its theoretical, healthy, tissue-sparing effects. However, … READ MORE …

PBRT vs. IMRT — another update

An article in yesterday’s Philadelphia Inquirer looked further into the question of the role of proton beam radiation therapy (PBRT) as a treatment for localized prostate cancer. … READ MORE …

Risk for GU side effects higher after SBRT than after IMRT?

A recent, retrospective analysis of Medicare data suggests that men who have first-line stereotactic body radiation therapy (SBRT) are at somewhat higher risk for genitourinary (GU) side effects than men who select intensity-moduated radiation therapy (IMRT). … READ MORE …

Hypofractionation of radiation therapy in treatment of localized prostate cancer

Many readers may be interested in reading an editorial just published in the Journal of Clinical Oncology that deals with “hypofractionation” (giving fewer doses of radiation therapy at higher dose levels) in treatment of localized prostate cancer. … READ MORE …

IMRT probably no better than 3D-CRT after radical prostatectomy

In another relatively unsurprising finding, a paper in JAMA Internal Medicine has suggested that– from a clinical point of view — there is little difference in the outcomes of men treated with older rather than newer forms of radiation therapy after first-line surgery for localized prostate cancer. … READ MORE …